WeVote
Log In

Bill

Bill

S 1584

An Act to prevent undue influence on prescriber behavior

194th Legislature (2025-2026) Introduced by Jason Lewis and 1 co-sponsor

Massachusetts bill restricts pharmaceutical company payments and gifts to prescribers to prevent financial incentives from influencing prescribing decisions and drug costs.

Bill reported favorably by committee and referred to the committee on Senate Ways and Means
0
WeVote Research Nonpartisan
Bill Summary · S 1584

Legislative bill overview

S 1584 aims to restrict pharmaceutical and medical device companies from providing certain gifts, payments, and benefits to healthcare prescribers that could influence their clinical decision-making. The bill establishes transparency requirements and limitations on industry-to-prescriber interactions, similar to existing federal Physician Payments Sunshine Law provisions but potentially with stricter Massachusetts-specific standards.

Why is this important

Prescriber behavior directly affects patient outcomes and healthcare costs. When financial incentives from drug and device manufacturers influence prescribing decisions, patients may receive more expensive or less appropriate treatments, driving up costs and potentially compromising care quality. This bill addresses a documented market practice that raises ethical and public health concerns.

Potential points of contention

  • Industry compliance costs: Pharmaceutical and medical device companies argue strict restrictions increase administrative burden and may reduce their ability to conduct legitimate medical education and research partnerships with providers
  • Definition scope: Ambiguity about what constitutes "undue influence" versus legitimate educational support, consulting fees, and speaking honorariums could create enforcement challenges or unintended restrictions on lawful relationships
  • Economic impact on innovation: Industry advocates contend that limiting relationships between manufacturers and prescribers may reduce prescriber input in product development and potentially discourage investment in Massachusetts-based pharmaceutical research and development

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.